Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Erasca, Inc.
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Sensei Biotherapeutics, Inc.
University of Alabama at Birmingham
SOLTI Breast Cancer Research Group
Salubris Biotherapeutics Inc